We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/10/2018 11:03 | That inverse H&S looks rather obvious to me....... a close above 1560 makes a long look rather tempting | toffeeman | |
31/10/2018 10:19 | £1 = $1.27 - good for GSK income ……;0) | tradermichael | |
30/10/2018 14:46 | come on GSK try and be blue before the results tomorrow then we can be blue again | nico9 | |
30/10/2018 13:48 | £1 = $1.28 | tradermichael | |
30/10/2018 08:17 | The world’s biggest businesses pumped an extra £3.5bn into research and development in the UK this year, as global spending growth hit a decade-high. Pharmaceuticals giants GSK and Astrazeneca were the biggest investors, with R&D spending of £6bn and £5.4bn, according to the report from PwC, followed by Fiat Chrysler’s £3.9bn and Rolls-Royce’s £1.1bn. | tradermichael | |
30/10/2018 08:16 | GlaxoSmithKline (LSE: GSK) has moved closer to realizing its strategy of submitting a regulatory filing for daprodustat in Japan next year. The UK pharma major has announced results from the second of three pivotal studies the filing, after the first trial yielded positive findings too. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being investigated as a potential treatment for anemia associated with chronic kidney disease (CKD). In the newly-announced results from the 52-week study of 271 haemodialysis-depend Results from the third study in non-dialysis dependent patients are anticipated in the first half of 2019. | tradermichael | |
29/10/2018 08:52 | IN @ 1518.126 …… ;0) | tradermichael | |
27/10/2018 11:12 | Im not sure it is a downtrend or sector specific, everything is getting marked down, alot of short selling, more sellers than buyers and a general correction going on, supercharged in the UK by brexit fiasco. | porsche1945 | |
26/10/2018 17:45 | I'm no chartist but I'm beginning to think the last 3 months activity is signifying a long term downtrend. Very happy to be proved wrong though. | rikky72 | |
26/10/2018 08:28 | £1 = $1.28 | tradermichael | |
26/10/2018 00:21 | Trump says he’s taking ‘revolutionary President Trump took his most significant action yet to lower drug prices, saying his administration is moving to stop “global freeloading” by foreign nations when it comes to the price that Americans pay for prescription drugs. The announcement is a sign that the president and his aides are shifting their focus to health care two weeks before the midterm elections. In a speech Thursday afternoon at the Department of Health and Human Services, Trump said his administration would be taking the “revolutionary “Americans pay more so other countries can pay less,” Trump said. “It’s wrong. It’s unfair.” | philanderer | |
25/10/2018 14:21 | Bad day for the sector, AZN down more, Shire similar fall to GSK | andyadvfn1 | |
25/10/2018 14:04 | Not a good day for GSK so far ……. :0( | tradermichael | |
25/10/2018 12:51 | Trump up to his usual nonsense again, strange timing about all these bomb packages in the US,right in the middle of the mid terms, couldn’t make it up. Not to difficult to work out what’s going on Right back to these, a few steps back again, bear trap surely ..with results due soon? | ny boy | |
25/10/2018 12:45 | It's all to do with the pig across the pond and his shenanigans about the pharma price crackdown. | abdullla | |
25/10/2018 11:57 | jadeticl3, See for comment on AZN. The article is not behind the FT's paywall. | zho | |
25/10/2018 11:46 | Why have the big two pharma’s fallen so far today? | jadeticl3 | |
25/10/2018 09:12 | Bear trap before the results, added on that drop. Added ABDP Added VOD BARC finally turning around bought 10,000 + 5000 early 160’s Some good opportunities about, have been switching out of many growth stocks into blue chips etc | ny boy | |
25/10/2018 09:10 | No body is flying today least our AZN. | abdullla | |
25/10/2018 08:57 | £1 = $1.29 ……. ;0) | tradermichael | |
24/10/2018 17:51 | Yes I noticed that a while back was pondering buying this and azn at the same time but just bought this instead wish I had bought both azn has been absolutely flying. | tim 3 | |
24/10/2018 15:48 | Be brilliant if they can raise the Dividend from 80p to 90p lol | nico9 | |
24/10/2018 15:28 | I've just noticed today how badly this as done next to AZN Looks like I invested in the wrong stock :o( | 1fox1 | |
24/10/2018 11:22 | If I see an inverse head and shoulders then the target price is 1650+ | toffeeman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions